Eckert & Ziegler SE Annual General Meeting Approves Significantly Higher Dividend

The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today approved the proposal of the Executive Board and Supervisory Board to pay a dividend of EUR 0.22 per share for the 2025 fiscal year, up from EUR 0.17 in the previous year. This represents a significant increase of approximately 29%, underscoring the company’s solid financial health and its commitment to delivering value to shareholders.

Held as an in-person event near the company headquarters in Berlin, the meeting saw 55.37% of the company’s share capital represented. Shareholders endorsed the actions of the Executive Board and Supervisory Board for the 2025 fiscal year and approved all agenda items by a large majority. The detailed voting results and the CEO’s presentation are available on the company’s website at https://www.ezag.com/investors/annual-general-meeting/.

Eckert & Ziegler SE, a leading specialist in isotope-related components for nuclear medicine and radiation therapy, employs over 1,000 people. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development to contract manufacturing and distribution. Its shares are listed in the TecDAX index of Deutsche Börse.

The dividend increase signals management’s confidence in the company’s future prospects and its ability to generate sustainable cash flows. For investors, this development matters as it reflects the company’s strong operational performance and its focus on rewarding shareholders. The radiopharmaceutical sector continues to grow, driven by increasing demand for targeted cancer therapies and diagnostic imaging, positioning Eckert & Ziegler favorably for continued success.